RAS testing in metastatic colorectal cancer : Excellent reproducibility amongst 17 Dutch pathology centers
In 2013 the European Medicine Agency (EMA) restricted the indication for anti- EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene, increasing the need for reliable RAS mutation testing. We evaluated the completeness and reproducibility of RAS-testing in the Netherlands. From 17 laboratories, tumor DNA of the first 10 CRC cases tested in 2014 in routine clinical practice was re-tested by a reference laboratory using a custom next generation sequencing panel. In total, 171 CRC cases were re-evaluated for hotspot mutations in KRAS, NRAS and BRAF. Most laborator... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2015 |
Schlagwörter: | Colorectal cancer / Metastasis / Next generation sequencing / Quality control / RAS / Oncology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26680928 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/357595 |